CA
NZ
UK
AU
IND
US
…
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Beta Bionics develops automated insulin-delivery systems, including the iLet bionic pancreas for people with insulin-requiring diabetes. Long-term growth drivers include rising diabetes prevalence and broader adoption of closed‑loop therapies, and investors may find the company attractive because it appears positioned to address a large unmet need with a differentiated automated-delivery approach.
Key risks include regulatory and clinical trial outcomes, commercialization and manufacturing execution, strong competition from established diabetes-device companies, ongoing losses with potential need for additional capital, and uncertain reimbursement.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Income before tax | -73.20M | -54.76M | -44.10M | -64.75M |
| Net income | -73.20M | -54.76M | -44.10M | -64.75M |
| Selling general administrative | 31.02M | 17.87M | 12.22M | 24.67M |
| Selling and marketing expenses | 61.40M | 37.09M | 11.99M | 8.83M |
| Gross profit | 55.54M | 35.89M | 6.31M | 0.18M |
| Reconciled depreciation | 2.88M | 2.28M | 2.09M | 2.09M |
| Ebit | - | -45.25M | -35.85M | -64.74M |
| Ebitda | -73.20M | -44.10M | -34.62M | -63.40M |
| Depreciation and amortization | - | 1.15M | 1.23M | 1.34M |
| Operating income | -71.68M | -45.25M | -35.85M | -65.84M |
| Other operating expenses | 171.93M | 110.38M | 47.84M | 66.02M |
| Interest expense | - | - | 0.07M | 0.01M |
| Interest income | 10.93M | 3.91M | 1.78M | 0.20M |
| Net interest income | 10.93M | 3.91M | 1.78M | 0.18M |
| Income tax expense | 0.00M | - | - | - |
| Total revenue | 100.25M | 65.12M | 11.99M | 0.18M |
| Total operating expenses | 127.22M | 81.14M | 42.16M | 66.02M |
| Cost of revenue | 44.71M | 29.24M | 5.69M | - |
| Total other income expense net | -1.52M | -9.51M | -8.25M | 1.09M |
| Net income from continuing ops | -73.20M | -54.76M | -44.10M | -64.75M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Total assets | 328.74M | 149.65M | 110.04M | 35.53M |
| Other current assets | 9.84M | 4.03M | 1.18M | 0.79M |
| Total liab | 41.13M | 73.63M | 51.43M | 22.53M |
| Total stockholder equity | 287.61M | 76.01M | 58.61M | 13.00M |
| Other current liab | 22.43M | 15.83M | 8.21M | 7.47M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -369.94M | -296.74M | -229.66M | -185.56M |
| Cash | 31.68M | 30.43M | 26.57M | 27.68M |
| Total current liabilities | 30.92M | 21.15M | 10.61M | 8.87M |
| Current deferred revenue | 1.56M | 0.94M | - | - |
| Net debt | -19.01M | -23.18M | -22.34M | -23.54M |
| Short term debt | 1.94M | 1.53M | 1.22M | 0.98M |
| Short long term debt total | 12.67M | 7.25M | 4.22M | 4.13M |
| Other stockholder equity | 657.14M | 51.31M | 26.42M | 15.53M |
| Total current assets | 267.90M | 132.92M | 103.62M | 28.47M |
| Long term investments | 45.43M | 0.00M | - | - |
| Short term investments | 187.55M | 73.14M | 70.18M | 0.00M |
| Net receivables | 17.12M | 12.00M | 4.45M | 0.00M |
| Inventory | 21.72M | 13.32M | 1.25M | 0.00M |
| Accounts payable | 5.00M | 2.85M | 1.17M | 0.43M |
| Accumulated other comprehensive income | 0.40M | 0.07M | 0.14M | - |
| Non currrent assets other | 0.18M | 5.30M | 0.22M | 0.19M |
| Non current assets total | 60.84M | 16.72M | 6.42M | 7.06M |
| Capital lease obligations | 7.30M | 7.25M | 4.22M | 4.13M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Investments | -157.51M | -3.48M | -69.69M | -0.77M |
| Total cashflows from investing activities | - | -3.48M | -69.69M | -0.77M |
| Total cash from financing activities | 214.87M | 55.62M | 101.03M | 56.78M |
| Net income | -73.20M | -54.76M | -44.10M | -64.75M |
| Change in cash | -30.53M | 3.87M | -1.11M | -4.20M |
| Begin period cash flow | 30.53M | 26.67M | 27.77M | 31.97M |
| End period cash flow | 31.68M | 30.53M | 26.67M | 27.77M |
| Total cash from operating activities | -50.92M | -48.27M | -32.45M | -60.21M |
| Issuance of capital stock | 210.12M | 59.66M | 101.00M | 56.39M |
| Depreciation | 2.88M | 2.28M | 2.09M | 2.09M |
| Other cashflows from investing activities | - | 0.05M | -69.29M | 0.00M |
| Change to inventory | -9.88M | -11.44M | -1.19M | 0.00M |
| Change to account receivables | -5.16M | -7.62M | -4.49M | 0.00M |
| Other cashflows from financing activities | - | 59.66M | 101.03M | 56.78M |
| Capital expenditures | 5.30M | 3.40M | 0.40M | 0.77M |
| Change in working capital | -8.99M | -12.15M | -6.36M | -2.79M |
| Stock based compensation | 16.38M | 6.38M | 5.66M | 6.10M |
| Other non cash items | 56.82M | 9.96M | 10.27M | -0.85M |
| Free cash flow | -56.22M | -51.67M | -32.85M | -60.98M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| BBNX Beta Bionics, Inc. Common Stock |
-0.83 4.72% |
16.75 | - | - | 5.74 | 2.00 | 3.63 |
| ABT Abbott Laboratories |
1.63 1.56% |
106.20 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 |
| MDT Medtronic PLC |
-0.57 0.59% |
96.54 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 |
| SYK Stryker Corporation |
-19.89 6.38% |
291.86 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 |
| SEMHF Siemens Healthineers AG |
-0.11 0.22% |
47.69 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 |
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Sean T. Saint PE | President, CEO & Director | 1976 |
| Mr. Stephen H. Feider | CFO, Treasurer & Secretary | 1990 |
| Mr. Mike Mensinger | Chief Product Officer | 1978 |
| Mr. David Henderson | Vice President of Operations | NA |
| Blake Beber | Head of Investor Relations | NA |
| Mr. Kevin Meinert | Vice President of Legal & Business Development | NA |
| Dr. Steven Russell M.D., Ph.D. | Chief Medical Officer | 1969 |
| Mr. Mark Hopman M.B.A., R.Ph. | Chief Commercial Officer | 1978 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...